Scholar Rock Holding (SRRK) Resubmits To The EMA, Is A 42% Discount Still Warranted?

Scholar Rock Holding (SRRK) has put apitegromab back in front of European regulators by resubmitting its Marketing Authorisation Application to the EMA after switching to an alternate fill finish facility with recent regulatory approvals.

Investors have been digesting a sharp pullback in Scholar Rock Holding’s share price, which is down about 27% over the past month and 25% over the last quarter. This comes even though the 1 year total shareholder return of 27% and roughly 4x total shareholder return over 3 years point to strong longer term momentum that this latest regulatory update may now test.

Spot similar rare disease and biotech opportunities under pressure and potential inflection by scanning our hand picked 20 high quality undiscovered gems alongside Scholar Rock Holding.

Scholar Rock Holding now sits between a sharp recent pullback and strong multi year returns, which raises a simple tension for investors. Are prices reacting to real cracks in the story, or just sentiment swinging around fresh regulatory headlines as we move into valuation work next?

Most Popular Narrative: 42% Undervalued

Scholar Rock Holding’s most followed valuation story pegs fair value at $70.44 against a last close of $40.52, which puts a big gap between where the shares trade and where that framework lands. The key question for you is whether the assumptions behind that gap still hold as apitegromab and the wider myostatin platform move through launch and expansion plans.

Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline.

Expansion into additional neuromuscular indications, such as the planned FORGE Phase II study in FSHD and the OPAL trial in infants and toddlers with SMA, broadens the addressable market beyond the initial SMA adult and pediatric population, which can affect future top line growth and earnings power.

See why 1 investors see Scholar Rock Holding as 42% undervalued.

Result: Fair Value of $70.44 (UNDERVALUED)

Still, the Scholar Rock Holding story carries real pressure points, including reliance on timely apitegromab approvals and heavy launch spending that could stretch losses if uptake disappoints.

Find out about the key risks to this Scholar Rock Holding narrative.

Next Steps

Feeling torn between the risks around apitegromab and the potential rewards across Scholar Rock Holding’s broader neuromuscular pipeline is normal, so move quickly, check the underlying data, and decide where you stand based on the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Scholar Rock Holding?

If you stop with just one opportunity, you may miss where the next meaningful move starts, so widen your lens and pressure test your thinking across other ideas.

• Target fresh upside potential by scanning the 20 high quality undiscovered gems that share resilient fundamentals and could be early in their recognition cycle.
• Protect your downside by reviewing the 32 resilient stocks with low risk scores that pair steadier fundamentals with lower overall risk scores.
• Anchor your portfolio with strength by checking the list of solid balance sheet and fundamentals (25 results) that back their stories with cleaner balance sheets and firmer financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com